Dolasynthen, Emi-Le (XMT-1660), Publications Clinical Activity of Emiltatug Ledadotin (Emi-Le), a B7-H4-Directed ADC, in Patients with TNBC who Received at Least One Prior Topoisomerase-1 Inhibitor (Topo-1) ADC
Immunosynthen, Publications, XMT-2056 XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Induces Innate Anti-Tumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Dolasynthen, Emi-Le (XMT-1660), Publications Initial Phase 1 Dose Escalation Data for Emi-Le (emiltatug ledadotin; XMT-1660)
Immunosynthen, Publications, XMT-2056 XMT-2056, a HER2-Targeted Immunosynthen Sting Agonist Antibody-Drug Conjugate, Induces Anti-tumor Activity at Low Doses in Preclinical Models
Dolasynthen, Emi-Le (XMT-1660), Publications Learnings from Translational and Clinical Development of Dolaflexin and Dolasynthen ADCs
Other, Other, Publications UPGRADE: Phase 1 Trial of the NaPi2b‑Directed Dolaflexin Antibody‑Drug Conjugate UpRi in Combination With Carboplatin in Patients With Platinum‑Sensitive Ovarian Cancer (PSOC)
Immunosynthen, Other, Publications Tumor Cell-Directed STING Agonist Antibody Drug Conjugates Induce Type III Interferons and Anti-Tumor Innate Immune Responses
Dolasynthen, Other, Publications The Impact of Scaffold, Linker, Homogeneity and Payload Selection on the Efficacy and Tolerability of Anti-Tubulin ADCs
Dolasynthen, Other, Publications Results From the Phase 1 Dose Escalation Study of XMT‑1592, a NaPi2b‑Directed Dolasynthen ADC
Other, Other, Publications UPLIFT: Results from the Phase 2 Trial of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-Directed Dolaflexin ADC in Platinum-Resistant Ovarian Cancer
